Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer

doi:10.1530/erc-18-0317

PMID: 30389903DOI: 10.1530/erc-18-0317Nov 6, 2018Paper

Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer

Endocrine-related Cancer

Neil PortmanC Elizabeth Caldon

Abstract

Three inhibitors of CDK4/6 kinases were recently FDA approved for use in combination with endocrine therapy, and they significantly increase the progression-free survival of patients with advanced estrogen receptor-positive (ER+) breast cancer in the first-line treatment setting. As the new standard of care in some countries, there is the clinical emergence of patients with breast cancer that is both CDK4/6 inhibitor and endocrine therapy resistant. The strategies to combat these cancers with resistance to multiple treatments are not yet defined and represent the next major clinical challenge in ER+ breast cancer. In this review, we discuss how the molecular landscape of endocrine therapy resistance may affect the response to CDK4/6 inhibitors, and how this intersects with biomarkers of intrinsic insensitivity. We identify the handful of pre-clinical models of acquired resistance to CDK4/6 inhibitors and discuss whether the molecular changes in these models are likely to be relevant or modified in the context of endocrine therapy resistance. Finally, we consider the crucial question of how some of these changes are potentially amenable to therapy.

References

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

Mar 1, 1993·Genes & Development·J KatoC J Sherr

Cancer cell cycles

Dec 6, 1996·Science·C J Sherr

Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.

Apr 18, 1997·The Journal of Biological Chemistry·O W PrallR L Sutherland

CDK inhibitors: positive and negative regulators of G1-phase progression

Jul 1, 1999·Genes & Development·C J Sherr, J M Roberts

Cyclin-dependent kinase pathways as targets for cancer treatment.

Apr 11, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Geoffrey I Shapiro

The regulation of INK4/ARF in cancer and aging

Oct 24, 2006·Cell·William Y Kim, Norman E Sharpless

Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia

Jun 1, 2007·Blood·Lisheng WangRoger Briesewitz

Retinoblastoma deficiency increases chemosensitivity in lung cancer

Sep 7, 2007·Cancer Research·William A ZagorskiMichael F Reed

GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy

Nov 21, 2007·Cellular Signalling·Fumi Takahashi-Yanaga, Toshiyuki Sasaguri

Cellular mechanisms of tumour suppression by the retinoblastoma gene.

Jul 25, 2008·Nature Reviews. Cancer·Deborah L Burkhart, Julien Sage

Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc.

Jul 1, 2009·Molecular and Cellular Biology·C Elizabeth CaldonElizabeth A Musgrove

Cell cycle kinases as therapeutic targets for cancer.

Jul 2, 2009·Nature Reviews. Drug Discovery·Silvia Lapenna, Antonio Giordano

Biological determinants of endocrine resistance in breast cancer.

Aug 25, 2009·Nature Reviews. Cancer·Elizabeth A Musgrove, Robert L Sutherland

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Oct 31, 2009·Breast Cancer Research : BCR·Richard S FinnDennis J Slamon

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

Apr 1, 2010·Cancer Research·Karine MichaudTodd Waldman

RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response

Oct 16, 2010·Cell Cycle·Adam ErtelErik S Knudsen

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

Feb 1, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gottfried E KonecnyDennis J Slamon

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

Mar 4, 2011·Endocrine-related Cancer·Chellappagounder ThangavelErik S Knudsen

Hallmarks of cancer: the next generation.

Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg

Cyclin D as a therapeutic target in cancer.

Jul 8, 2011·Nature Reviews. Cancer·Elizabeth A MusgroveRobert L Sutherland

The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments

Jul 22, 2011·Cell Cycle·Agnieszka K WitkiewiczErik S Knudsen

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.

Nov 19, 2011·Cancer Cell·Lars AndersPiotr Sicinski

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells

May 9, 2012·Molecular Cancer Therapeutics·C Elizabeth CaldonElizabeth A Musgrove

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.

Jul 7, 2012·Cell Cycle·Jeffry L DeanErik S Knudsen

RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer

Jul 20, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Agnieszka K WitkiewiczErik S Knudsen

The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma

Oct 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karen E Sheppard, Grant A McArthur

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

Jan 9, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rinath JeselsohnVincent A Miller

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Jun 13, 2014·Investigational New Drugs·Lawrence M GelbertAlfonso de Dios

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

Jul 9, 2014·Cancer Cell·Sadhna R VoraJeffrey A Engelman

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer

Aug 27, 2014·Oncotarget·Jorge FrancoErik S Knudsen

Cyclin-dependent kinases

Sep 3, 2014·Genome Biology·Marcos Malumbres

CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.

Oct 25, 2014·Blood·Ruth ScheicherVeronika Sexl

The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes

Dec 9, 2014·Cell Cycle·Sabine PaternotPierre P Roger

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment

Dec 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Angela DeMichelePeter O'Dwyer

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Dec 20, 2014·The Lancet Oncology·Richard S FinnDennis J Slamon

Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS

Jan 6, 2015·Oncotarget·Barbie Taylor-HardingW Ruprecht Wiedemeyer

Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors

Jan 28, 2015·Cancers·Marion PeyressatreMay C Morris

The history and future of targeting cyclin-dependent kinases in cancer therapy

Jan 31, 2015·Nature Reviews. Drug Discovery·Uzma AsgharErik S Knudsen

CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma

Mar 27, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mary E OlanichFrederic G Barr

Forging a signature of in vivo senescence

Jun 25, 2015·Nature Reviews. Cancer·Norman E Sharpless, Charles J Sherr

Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

Jul 8, 2015·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Thomas J RaubAlfonso De Dios

DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer.

Jul 15, 2015·Nature Communications·Andrew StoneSusan J Clark

Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer

Sep 22, 2015·ACS Chemical Biology·Natalia J SumiUwe Rix

Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer

Oct 10, 2015·Cell·Giovanni CirielloCharles M Perou

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Nov 13, 2015·Science Translational Medicine·Gaia SchiavonNicholas C Turner

T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes

Dec 19, 2015·Gut·Daniele MennonnaPaolo Dellabona

Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6

Mar 19, 2016·Cancer Research·Akihiro YoshidaJ Alan Diehl

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer

Mar 30, 2016·Cancer Research·Maria Teresa Herrera-AbreuVioleta Serra

Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer

May 18, 2016·The American Journal of Pathology·Cansu KarakasKhandan Keyomarsi

❮ Previous

Next ❯

Citations

The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer

Feb 6, 2019·International Journal of Molecular Sciences·Sarah AlexandrouC Elizabeth Caldon

Highlights in Resistance Mechanism Pathways for Combination Therapy

Sep 5, 2019·Cells·João M A DelouHelena L Borges

Therapy options after CDK4/6 inhibitors for HR+, HER2- postmenopausal metastatic/recurrent breast cancer in Japan: a role for mammalian target of rapamycin inhibitors?

Jul 3, 2020·Future Oncology·Takahiro Nakayama, Fumie Fujisawa

Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.

Jul 23, 2020·Cancer Medicine·Deborah L Toppmeyer, Michael F Press

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

Aug 10, 2019·Frontiers in Oncology·Amelia McCartneyAngelo Di Leo

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions.

Sep 5, 2020·International Journal of Molecular Sciences·Rossana RoncatoGiuseppe Toffoli

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.

Aug 17, 2020·Breast Cancer Research : BCR·Neil A O'BrienDennis J Slamon

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

Aug 14, 2020·Breast Cancer Research : BCR·Neil PortmanElgene Lim

Computer-Aided Ligand Discovery for Estrogen Receptor Alpha.

Jun 18, 2020·International Journal of Molecular Sciences·Divya BafnaArtem Cherkasov

Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment.

Aug 28, 2020·Nature Communications·Ying JiHuan Meng

Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows.

Jun 18, 2020·Molecular Cancer Therapeutics·Patrick J RobertsErik S Knudsen

The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer

Jan 8, 2020·Molecular Cancer Therapeutics·Scott F Schoninger, Stacy W Blain

Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

Jan 16, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amelia McCartneyLuca Malorni

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).

Sep 4, 2019·Bioorganic & Medicinal Chemistry Letters·Concepción Sánchez-MartínezAlfonso de Dios

PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.

Oct 14, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Marzia Del ReFederico Cucchiara

The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.

Jan 20, 2021·Nature Medicine·Theresa E HickeyWayne D Tilley

CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care.

Jan 29, 2021·Asia-Pacific Journal of Clinical Oncology·Rina HuiJodi Lynch

Fenhexamid induces cancer growth and survival via estrogen receptor-dependent and PI3K-dependent pathways in breast cancer models.

Jan 24, 2021·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Ryeo-Eun GoKyung-Chul Choi

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer

Dec 29, 2020·Frontiers in Pharmacology·Zhen LiCeshi Chen

Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.

Jan 29, 2021·Genes·Kamal PandeyYong Wha Moon

Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.

Jan 8, 2021·Molecular Biology Reports·Georgia GomatouElias Kotteas

Smoothened-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models.

Jan 22, 2021·The Journal of Clinical Investigation·Vikas DaggubatiDavid R Raleigh

Challenges and Opportunities in Cancer Drug Resistance.

Jul 22, 2020·Chemical Reviews·Richard A WardPaul D Smith

A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.

Jul 25, 2020·European Journal of Medicinal Chemistry·Brilliant N MarakVed Prakash Singh

Development of CDK4/6 Inhibitors: A Five Years Update.

Apr 4, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Alessandra AmmazzalorsoMarialuigia Fantacuzzi

Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.

Apr 16, 2021·Scientific Reports·Kanako HagioHiroko Yamashita

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer.

May 21, 2021·Nature Communications·Nindo B PunturiSvasti Haricharan

Liquid Biopsy: A New Tool for Overcoming CDKi Resistance Mechanisms in Luminal Metastatic Breast Cancer.

Jun 3, 2021·Journal of Personalized Medicine·Miriam González-CondeClotilde Costa

Targeting CDK9 for the Treatment of Glioblastoma.

Jul 3, 2021·Cancers·Alice RanjanJing Wu

The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time.

Jul 11, 2021·Journal of Cancer Research and Clinical Oncology·Mayu OnoKen-Ichi Ito

Combined endocrine and targeted therapy in luminal breast cancer.

Aug 3, 2021·Expert Review of Anticancer Therapy·Marcelle GoldnerNoam Pondé

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).

Mar 17, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Aditya BardiaStacy Moulder

Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer.

Aug 14, 2021·Cancer Gene Therapy·Olesya A KharenkoEdward H van der Horst

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.

Aug 27, 2021·Nature Communications·Carla L AlvesHenrik J Ditzel

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.

Feb 5, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carmine De AngelisRachel Schiff

Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression.

Oct 14, 2021·NPJ Breast Cancer·Christina Horr, Steven A Buechler

Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.

Nov 6, 2021·Molecular Biology Reports·Flávia MirandaFernando Schmitt

Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis.

Nov 18, 2021·Bioengineered·Jia-Ning ZhangWei-Ping Zhou

NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.

Feb 6, 2022·Scientific Reports·Raksha BhatMeghana V Trivedi

❮ Previous

Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.